Carregant...
The Albumin in Acute Stroke (ALIAS) Part 1 Trial: An exploratory efficacy analysis
BACKGROUND: The ALIAS Part 2 Trial is directly testing whether 2g/kg of 25% human albumin (ALB) administered intravenously within 5 hours of ischemic stroke onset results in improved clinical outcome. Recruitment into Part 1 of the ALIAS Trial was halted for safety reasons. ALIAS Part 2 is a new, re...
Guardat en:
| Autors principals: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2011
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3118599/ https://ncbi.nlm.nih.gov/pubmed/21546491 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/STROKEAHA.110.610980 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|